EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia

Nobuaki Ito, Naoko Hidaka, Hajime Kato

Endocrinology and Metabolism · 30.04.2024 · 39 (2) · 255-261

DOI: 10.3803/enm.2023.1908 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism, erschienen am 30.04.2024. Verfasst von Nobuaki Ito und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Fibroblast Growth Factor-23, Osteomalacia, Fibroblast Growth Factors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast growth factor 23 (FGF23) is a pivotal humoral factor for the regulation of serum phosphate levels and was first identified in patients with autosomal dominant hypophosphatemic rickets and tumor-induced osteomalacia (TIO), the most common form of acquired FGF23-related hypophosphatemic rickets/osteomalacia (FGF23rHR). After the identification of FGF23, many other inherited and acquired forms of FGF23rHR were reported. In this review article, the detailed features of each acquired FGF23rHR are discussed, including TIO, ectopic FGF23 syndrome with malignancy, fibrous dysplasia/McCune-Albright syndrome, Schimmelpenning-Feuerstein-Mims syndrome/cutaneous skeletal hypophosphatemia syndrome, intravenous iron preparation-induced FGF23rHR, alcohol consumption-induced FGF23rHR, and post-kidney transplantation hypophosphatemia. Then, an approach for the differential diagnosis and therapeutic options for each disorder are concisely introduced. Currently, the majority of endocrinologists might only consider TIO when encountering patients with acquired FGF23rHR; an adequate differential diagnosis can reduce medical costs and invasive procedures such as positron emission tomography/computed tomography and venous sampling to identify FGF23-producing tumors. Furthermore, some acquired FGF23rHRs, such as intravenous iron preparation/alcohol consumption-induced FGF23rHR, require only cessation of drugs or alcohol to achieve full recovery from osteomalacia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth Factor-23OsteomalaciaFibroblast Growth FactorsHumansParaneoplastic SyndromesHypophosphatemiaRickets, HypophosphatemicNeoplasms, Connective Tissue

Stichwörter der Autor:innen

Fibroblast growth factor-23Fibrous dysplasiaIron deficienciesLung neoplasmsProstatic neoplasmsSchimmelpenning-Feuerstein-Mims syndromeTumor-induced osteomalacia

Substanzen

Fibroblast Growth Factor-23FGF23 protein, humanFibroblast Growth Factors

Autor:innen und Institutionen

  • Division of Nephrology and Endocrinology, The University of Tokyo Hospital, Tokyo, Japan.
  • Osteoporosis Center, The University of Tokyo Hospital, Tokyo, Japan.

Zitieren

APA

Ito, N., Hidaka, N., & Kato, H. (2024). Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia. Endocrinology and Metabolism, 39(2), 255-261. https://doi.org/10.3803/enm.2023.1908

Vancouver

Ito N, Hidaka N, Kato H. Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia. Endocrinology and Metabolism. 2024;39(2):255-261. doi:10.3803/enm.2023.1908

BibTeX
@article{Ito2024,
  author = {Ito, Nobuaki and Hidaka, Naoko and Kato, Hajime},
  title = {Acquired Forms of Fibroblast Growth Factor 23-Related Hypophosphatemic Osteomalacia},
  journal = {Endocrinology and Metabolism},
  year = {2024},
  volume = {39},
  number = {2},
  pages = {255--261},
  doi = {10.3803/enm.2023.1908}
}
Kostenlos starten →